FDA
-
-
-
-
-
-
-
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
-
-
-
-
-
-
-
Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients
-
-
-
-
-
-
-
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call
-
-
-
-
-
-
-
NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call
-
-
-
-
-
-
-
Pre-Open Stock Movers 01/18: (ATVI) (BBI) (NURO) Higher; (RMED) (GPS) (GS) Lower (more...)
-
-
-
-
-
-
-
NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia
-
-
-
-
-
-
-
NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference Call
-
322,873 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

